Exclusive: Post-Lilly deal, Scorpion crew carries on with $177M at Antares
BOSTON – Antares Therapeutics is in a unique position. The Boston and South San Francisco biotech said Tuesday it's raised a $177 million Series A, but it's much further along than most drug developers at ...
BOSTON – Antares Therapeutics is in a unique position.
The Boston and South San Francisco biotech said Tuesday it's raised a $177 million Series A, but it's much further along than most drug developers at ...
